Issue 2/2012
Content (16 Articles)
Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients
E. Blank, N. Willich, R. Fietkau, W. Popp, J. Schaller-Steiner, H. Sack, F. Wenz
Dosimetric integration of daily mega-voltage cone-beam CT for image-guided intensity-modulated radiotherapy
A. Zabel-du Bois, S. Nill, S. Ulrich, U. Oelfke, B. Rhein, P. Haering, S. Milker-Zabel, A. Schwahofer
Breast cancer and funnel chest
M. Uhl, F. Sterzing, G. Habl, K. Schubert, H. Holger, J. Debus, K. Herfarth
Salvage radiotherapy in patients with recurrent esophageal carcinoma
K. Fakhrian, N. Gamisch, T. Schuster, R. Thamm, M. Molls, H. Geinitz
Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis
D. Rades, J.D. Kueter, J. Gliemroth, T. Veninga, A. Pluemer, S.E. Schild
Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors
C. Gani, A.C. Müller, F. Eckert, C. Schroeder, B. Bender, G. Pantazis, M. Bamberg, B. Berger
Radiotherapy with and without temozolomide in elderly patients with glioblastoma
M. Niyazi, S.B. Schwarz, B. Suchorska, C. Belka
Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy
I. Fotina, C. Lütgendorf-Caucig, M. Stock, R. Pötter, D. Georg
Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation
C. Blattmann, S. Oertel, M. Thiemann, K.J. Weber, P. Schmezer, O. Zelezny, R. Lopez Perez, A.E. Kulozik, J. Debus, V. Ehemann
Radiosensitizing effect of epothilone B on human epithelial cancer cells
T. Baumgart, G. Klautke, S. Kriesen, S.A. Kuznetsov, D.G. Weiss, R. Fietkau, G. Hildebrandt, K. Manda
Numerical deconvolution to enhance sharpness and contrast of portal images for radiotherapy patient positioning verification
H.K. Looe, Y. Uphoff, D. Harder, B. Poppe, K.C. Willborn
RTOG-Studie 0324: Cetuximab bei Patienten mit nicht-kleinzelligem Bronchialkarzinom
C. Nieder
Capecitabin plus Oxaliplatin verglichen mit Fluorouracil und Folinsäure als adjuvante Therapie bei Kolonkarzinom im Stadium III
D. Arnold